scholarly journals Long-term safety and disease control with ruxolitinib cream among patients with atopic dermatitis based on previous medication history: Pooled results from two phase 3 studies

2021 ◽  
Vol 5 (6) ◽  
pp. s65
Author(s):  
Andrew Blauvelt ◽  
Lawrence Eichenfeld ◽  
Michael Kuligowski ◽  
May Venturanza ◽  
Kang Sun ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Disease Control ◽  
Medication History ◽  
Phase 3 ◽  
Two Phase ◽  
Previous Medication

N/A

scholarly journals Long-Term Safety and Disease Control With Ruxolitinib Cream in Atopic Dermatitis: Results From Two Phase 3 Studies

2021 ◽  
Vol 5 (6) ◽  
pp. s63
Author(s):  
Kim Papp ◽  
Jacek Szepietowski ◽  
Leon Kircik ◽  
Darryl Toth ◽  
Lawrence Eichenfeld ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Disease Control ◽  
Phase 3 ◽  
Two Phase

N/A

scholarly journals 208 Long-Term Safety and Disease Control With Ruxolitinib Cream in Atopic Dermatitis: Results From Two Phase 3 Studies

2021 ◽  
Vol 141 (10) ◽  
pp. S184
Author(s):  
K. Papp ◽  
J. Szepietowski ◽  
L. Kircik ◽  
D. Toth ◽  
L. Eichenfield ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Disease Control ◽  
Phase 3 ◽  
Two Phase

scholarly journals Long-Term Safety and Disease Control With Ruxolitinib Cream in Patients With More Severe Atopic Dermatitis: Pooled Results From Two Phase 3 Studies

2021 ◽  
Vol 5 (6) ◽  
pp. s66
Author(s):  
Eric Simpson ◽  
Leon Kircik ◽  
Andrew Blauvelt ◽  
Michael Kuligowski ◽  
May Venturanza ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Disease Control ◽  
Severe Atopic Dermatitis ◽  
Phase 3 ◽  
Two Phase

N/A

27482 Efficacy of ruxolitinib cream among patients with atopic dermatitis based on previous medication history: Pooled results from two phase 3 studies

2021 ◽  
Vol 85 (3) ◽  
pp. AB148
Author(s):  
Andrew Blauvelt ◽  
Lawrence F. Eichenfield ◽  
Michael E. Kuligowski ◽  
May E. Venturanza ◽  
Kang Sun ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Medication History ◽  
Phase 3 ◽  
Two Phase ◽  
Previous Medication

Long-term Efficacy and Safety of Brodalumab in Patients With Psoriasis Disease Duration <10 and ≥10 Years: Analysis of Two Phase 3 Studies

2019 ◽  
Vol 3 ◽  
pp. S25
Author(s):  
Benjamin Ehst ◽  
George Han ◽  
Scott Guenthner ◽  
Kimberly Eads ◽  
Abby Jacobson
Keyword(s):  
Disease Duration ◽  
Efficacy And Safety ◽  
Phase 3 ◽  
Two Phase ◽  
Term Efficacy

Abstract not available.

Sign in / Sign up

Export Citation Format

Share Document